BRCA1/2 in ovarian cancer

1 EU-approved indication in ovarian cancer needs a BRCA1/2 result: olaparib (maintenance, advanced).

Histology

Line of therapy

Approved indications, Ovarian cancer
DrugBiomarker requirementRegimenSettingConditions
BRCA1/2 mutation1
Olaparib
Lynparza
BRCA1/2 mutation (germline and/or somatic)
Monotherapy
Maint.
advanced
High-grade only; In complete or partial response following completion of first-line platinum-based chemotherapy

8 approvals for Ovarian need no biomarker and apply whatever the result. All approvals for Ovarian

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Olaparib (Lynparza)
    maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.